

1 **Inter-laboratory optimization and evaluation of a serological assay for diagnosis of human**

2 **baylisascariasis**

3

4 Lisa N. Rascoe<sup>1\*</sup>, Cynthia Santamaria<sup>2\*</sup>, Sukwan Handali<sup>1</sup>, Sriveny Dangoudoubiyam<sup>3,4</sup>, Kevin R. Kazacos<sup>3</sup>,

5 Patricia P. Wilkins<sup>1#</sup>, Momar Ndao<sup>2#</sup>

6 **Affiliations**

7 Division of Parasitic Diseases & Malaria, Centers for Disease Control and Prevention, Atlanta, GA;<sup>1</sup>

8 National Reference Centre for Parasitology, Research Institute of the McGill University Health Centre,

9 Montreal, Canada;<sup>2</sup> Department of Comparative Pathobiology, Purdue University, West Lafayette, IN;<sup>3</sup>

10 Present address Gluck Equine Research Center, University of Kentucky, Lexington, KY.<sup>4</sup>

11

12

13 Running title: Human baylisascariasis immunodiagnosis

14

15 #Corresponding author. Mailing address: Division of Parasitic Diseases & Malaria, MS D-64, Centers for

16 Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, [pwilkins@cdc.gov](mailto:pwilkins@cdc.gov); NRCP,

17 Montreal General Hospital Research Institute R3-137, Montreal, Quebec, H3G, 1A4, Canada,

18 [momar.ndao@mcgill.ca](mailto:momar.ndao@mcgill.ca)

19

20

21 \* These authors contributed equally to this research.

22

23

24

25

26

27

28 **Abstract**

29 A Western blot assay using a recombinant protein, rBpRAG1, was developed for the diagnosis of human  
30 baylisascariasis concurrently by the Centers for Disease Control and Prevention (CDC) in Atlanta, GA and  
31 the National Reference Centre for Parasitology (NRCP) in Montreal, Canada. The assay performance was  
32 assessed by testing 275 specimens at CDC and 405 specimens at NRCP. Twenty specimens from 16 cases  
33 of baylisascariasis were evaluated. Eighteen were positive, with the assay correctly identifying 14 of 16  
34 patients. The rBpRAG1 Western blot showed no cross-reactivity with *Toxocara* positive serum and had  
35 an overall sensitivity of 88% and specificity of 98%.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 Human baylisascariasis, caused by the raccoon roundworm *Baylisascaris procyonis*, results from  
52 infection of a human host with *B. procyonis* L3 larvae. Subsequent neural, visceral, and ocular larva  
53 migrans syndromes may occur. The severity of disease is dependent on the number of infective eggs  
54 ingested and the tissues affected by larval migration (1). *B. procyonis* has emerged in recent years as  
55 one of the most serious causes of larva migrans in humans (2). Pathogenesis is similar to that of  
56 toxocariasis, but usually the disease is more severe and the migration of *B. procyonis* larvae through  
57 tissues is more aggressive than that of *Toxocara* spp. (3). Unlike *Toxocara* spp., *B. procyonis* larvae  
58 continue to grow while migrating, increasing the likelihood of severe neurological disease. Infected  
59 patients present with symptoms ranging from mild to severe neurologic dysfunction which may  
60 deteriorate rapidly to marked postural and locomotor problems, blindness, seizures, coma, and death,  
61 especially if larvae invade the brain in large numbers (2,4). Due to the limited timeframe between onset  
62 of symptoms and severe neurological disease, early detection is imperative for patient outcome and  
63 survival. Currently, definitive diagnosis is dependent on identification of larvae in biopsy or autopsy  
64 specimens (4). Although CT and MRI scans are an adjunct for diagnosis, they cannot definitively  
65 differentiate between *Baylisascaris* infection and infections with other eosinophilic meningitis-causing  
66 parasites. In most cases, changes visualized by neuroimaging lag behind severe clinical manifestations  
67 (3,4). The most efficient and least invasive method for diagnosis is serology. Diagnostic assays using  
68 native excretory-secretory (ES) antigen from *B. procyonis* infective larvae were useful, but cross-  
69 reactivity, particularly by *Toxocara* specific antibodies, remained a problem in enzyme-linked  
70 immunosorbent assays (ELISA) (5). Better results were obtained using Western blot tests, which could  
71 differentiate *Baylisascaris* from *Toxocara* infection, although both tests had to be performed (6). The

72 differential diagnosis of baylisascariasis must rule out toxocariasis because both parasites can cause  
73 similar clinical problems and have overlapping geographical distributions (5).

74         Recently, serological assays for baylisascariasis have improved greatly with the use of a  
75 recombinant protein (5, 7). An ELISA was developed based on the *Baylisascaris procyonis* RAG1  
76 recombinant protein (*rBpRAG1*) and early testing showed no cross-reactivity with *Toxocara spp.*  
77 infections (7). However, in a more recent study testing a total of 384 human patient serum specimens,  
78 including 20 patients with clinical *Baylisascaris* larva migrans, 137 patients with other parasitic infections  
79 (8 helminth and 4 protozoan), and 227 with unknown/suspected parasitic infections, the rBpRAG1 ELISA  
80 showed a sensitivity of 85% and specificity of 87% with 25% cross-reactivity with *Toxocara sp.* infections  
81 (5). Previously, diagnostics for baylisascariasis were only available at Purdue University, but recently the  
82 rBpRAG1 reagents were transferred to two separate national centers for assay development and  
83 independent optimization. In the present study, a sensitive and specific Western blot for the diagnosis  
84 of *B. procyonis* infections in humans based on the rBpRAG1 recombinant protein was developed and  
85 optimized for use in both the Centers for Disease Control and Prevention (CDC) Parasitic Diseases  
86 Reference Diagnostic Laboratory in Atlanta, Georgia and the National Reference Centre for Parasitology  
87 (NRCP) in Montreal, Canada.

#### 88 **Materials and Methods**

89         Sera for assay optimization. Both institutions used a positive control anti-*B. procyonis* serum  
90 from a baboon that developed severe NLM after experimental infection with *B. procyonis* embryonated  
91 eggs. A normal human serum pool was constructed from 5 serum samples from negative, presumably  
92 healthy United States residents with no history of international travel. At CDC, a *Toxocara*-positive  
93 serum pool was prepared by combining 10 EIA positive serum samples.

94         Serum panels for determinations of diagnostic sensitivity and specificity. To determine diagnostic  
95 sensitivity and specificity of the assay at CDC, a total of 275 human serum specimens were tested

96 including 15 sera and one CSF from patients diagnosed with *B. procyonis*, 109 sera from patients with  
97 other diseases, and 150 sera from North Americans with no history of international travel. At NRCP, a  
98 total of 405 samples were used for an independent evaluation of sensitivity and specificity, consisting of  
99 nine sera and two CSF specimens from seven patients with baylisascariasis, 264 sera from patients with  
100 other diseases, and 130 sera from negative, presumably healthy individuals. All serum samples were  
101 used in compliance with protocols approved by the ethical review boards of the participating  
102 institutions.

103 Expression and purification of rBpRAG1 and development of Western blot assays. The pRSET  
104 C/RAG1 plasmid was obtained by CDC and NRCP in 2012 from Purdue University. Expression,  
105 purification, and Western blot optimization were performed independently at each center based on the  
106 methods of Dangoudoubiyam et al. (7).

107 Expression and purification of rBpRAG1 at CDC. At CDC, the pRSETC/RAG1 plasmid was  
108 transformed into BL21 (DE3) pLysS and the recombinant colonies were selected from LB agar plates  
109 containing 34µg/mL chloramphenicol and 100µg/mL ampicillin. Colonies were grown in LB Broth  
110 containing 34µg/mL chloramphenicol and 100µg/mL ampicillin overnight at 37°C. Expression of  
111 rBpRAG1 was achieved 3 hours after adding 0.1 mM isopropyl-β, D-thiogalactopyranoside (IPTG) to the  
112 overnight culture. Samples of the induced and non-induced cultures were collected and separated using  
113 SDS-PAGE under non-reducing conditions. The gels were visualized and analyzed using Western blotting  
114 following previously described methods (8) with anti-HIS and anti-Xpress antibodies (Life Technologies),  
115 *B. procyonis* infected baboon serum, and a normal human serum pool. All primary antibodies were  
116 diluted in PBS/0.3% Tween-20 (PBS-Tw)/5% milk with the anti-HIS and anti-Xpress antibodies at a  
117 1:5,000 dilution and the baboon and normal human serum pool at a 1:100 dilution. Human serum and  
118 CSF specimens were tested using a 1:100 or 1:10 dilution, respectively, in PBS/0.3% Tween-20 (PBS-  
119 Tw)/5% milk. The secondary antibody used for anti-HIS and anti-Xpress antibodies was a HRP-

120 conjugated goat anti-mouse IgG at a 1:8,000 dilution in PBS-Tw and HRP-conjugated goat anti-human  
121 IgG at a 1:8,000 dilution in PBS-Tw for the baboon and normal human serum pools. The membranes  
122 were incubated with 3,3'-diaminobenzidine (DAB) and H<sub>2</sub>O<sub>2</sub> solution for band detection.

123 Purification of the poly-histidine-tagged rBpRAG1 fusion protein was performed using 6M urea  
124 as the denaturing agent and TALON metal affinity resins (Clontech, Inc., Mountain View, CA) (7). Eluted  
125 fractions were collected and analyzed by SDS- PAGE and Western blotting with anti-HIS antibodies.  
126 Protein concentration was measured using the BCA Protein Assay (Pierce, Rockford, IL).  
127 For determination of antigen purity and optimal concentration, four concentrations of the rBpRAG1  
128 protein, 18.3, 37.5, 75, 150 ng/well, were run on 4-12% NuPage Bis-Tris gradient gels (Life Technologies),  
129 blotted, and probed with anti-*B. procyonis* baboon serum, anti-*Toxocara* positive serum pool, and a  
130 normal human serum pool using the previously described method. For high-throughput testing of the  
131 CDC panel of sera, 2.75 µg f rBpRAG1 antigen was loaded and electrophoresed on a Criterion XT 4-12%  
132 Bis-Tris gel with an 11cm IPG well (Bio-Rad Laboratories, Hercules, CA), transferred to nitrocellulose, and  
133 cut into 2.5 mm strips.

134 Expression and purification of rBpRAG1 at NRCP. At the NRCP, expression and purification of  
135 the rBpRAG1 protein was modified from the protocol described by Dangoudoubiyam et al. (4). One liter  
136 of SOB medium with final concentrations of 34 µg/mL chloramphenicol and 100 µg/mL ampicillin was  
137 inoculated with an overnight culture of BL21(DE3)/pLysS competent *E. coli* transformed with the pRSET  
138 C/RAG1 expression plasmid. The cultures were incubated at 37°C with shaking at 225 rpm until the  
139 optical density (OD) at 600nm reached 1.0 to 1.2. Isopropyl-1-β-D-thio-1-galactopyranoside (IPTG) was  
140 added to a final concentration of 0.5 mM, and the cultures further incubated at 37°C with shaking for  
141 3.5 hours. The cells were harvested by centrifugation at 3,000 x g for 10 minutes at room temperature  
142 (RT) and stored at -80°C. Cell pellets were lysed under denaturing conditions with purification buffer (20  
143 mM Tris-HCl, pH 8.5, 8 M urea, 500 mM NaCl, 10 mM β-mercapthoethanol, 20 mM imidazole and 5

144 ug/mL DNaseI) and incubated on a rotary shaker for 30 minutes at RT. After centrifugation at 24,000 x g  
145 for 20 minutes at RT, the recombinant 6xHis-tagged RAG1 protein was purified using Superflow Ni-NTA  
146 resin (Qiagen, Venlo, NL). Five mL of 50% saturated resin was equilibrated with 10 column volumes of  
147 purification buffer. The supernatant containing the rBpRAG1 protein was added to the equilibrated resin  
148 and allowed to bind on a rotary shaker for 1 hour at RT. The resin-lysate mixture was transferred to a  
149 polypropylene column and packed under gravity flow. Six wash buffers of decreasing concentrations of  
150 urea (8, 7, 6, 5, 4 and 3 M) in 20 mM Tris-HCl, pH 8.5, 500 mM NaCl, 10 mM  $\beta$ -mercapthoethanol and 20  
151 mM imidazole were applied to the column and drained by gravity flow. The bound protein was eluted in  
152 8 column volumes (20 mL) of elution buffer (20 mM Tris-HCl, pH 8.5, 500 mM NaCl, 3 M urea, 10 mM  $\beta$ -  
153 mercapthoethanol, and 150 mM imidazole). The eluted protein was dialyzed against TE buffer (10 mM  
154 Tris-HCl, pH 7.5, 1 mM EDTA) using Zeba Desalt Spin Columns (Pierce, Rockford, IL) and protein  
155 concentration was measured by BCA assay (Pierce) according to the manufacturer's protocols.

156       Expression and purification of the rBpRAG1 antigen was verified by SDS-PAGE and immunoblot.  
157 Non-transformed BL21 (DE3) pLysS competent *E. coli* cells were used as a control to assess for rBpRAG1  
158 expression. Aliquots of both transformed and non-transformed, induced and non-induced cultures were  
159 collected at various time-points and separated on Mini-PROTEAN 4-15% TGX gradient gels (Bio-Rad  
160 Laboratories) under reducing conditions. Separated proteins were transferred to nitrocellulose  
161 membranes by iBlot dry transfer (Life Technologies) using the default 7-minute protocol. Non-specific  
162 sites were blocked with 5% skim milk in 0.05% PBST (0.05% Tween 20 in PBS) for 1 hour at RT.  
163 Membranes were incubated overnight at 4°C with a mouse monoclonal anti-poly-histidine serum at  
164 1:6,000 (Sigma, St-Louis, MI) followed by incubation with HRP-conjugated anti-mouse IgG at a 1:50,000  
165 dilution (GE Healthcare, Little Chalfont, UK). The purified and desalted rBpRAG1 protein was assessed  
166 for reactivity with human serum. The nitrocellulose membranes were probed with either a pool of  
167 human serum specimens (n =3) positive for *Baylisascaris procyonis* at a dilution of 1:100 or a pool of

168 healthy human sera (n=3) at 1:100 and incubated with HRP-conjugated anti-human IgG at a 1:100,000  
169 dilution (Perkin-Elmer, Waltham, MA). All membranes were incubated with the chemiluminescent  
170 substrate, in SuperSignal West Pico, (Pierce) and exposed to autoradiography film.

171 For determination of optimal antigen concentration, four amounts of the rBpRAG1 protein (128,  
172 256, 512 and 1024 ng/well) were run on 4-12% NuPage Bis-Tris gradient gels (Life Technologies) under  
173 reducing conditions and transferred to nitrocellulose membranes as described above. The membranes  
174 were probed with the same pools of *B. procyonis* positive and healthy human sera used above at a  
175 dilution of 1:100 but probed with HRP-conjugated anti-human IgG at a dilution of 1:25,000. The  
176 membranes were incubated with DAB/H<sub>2</sub>O<sub>2</sub> solution.

177 For high-throughput testing of sera, 6 µg of rBpRAG1 protein was separated on 1D well 4-12%  
178 NuPage Bis-Tris gradient gels (Life Technologies) and transferred onto nitrocellulose for Western blot  
179 analysis using a Mini-PROTEAN II Multiscreen Apparatus (Bio-Rad Laboratories). Human serum and CSF  
180 specimens were tested at a dilution of 1:100 and incubated with anti-human IgG-HRP at 1:5,000.  
181 Membranes were developed with DAB/H<sub>2</sub>O<sub>2</sub> solution.

## 182 **Results**

183 Expression of rBpRAG1 was monitored by the presence of a 37 kDa band detected by the anti-  
184 His antibody only in cells transformed with the expression clone. At the NRCP, recombinant RAG1 was  
185 expressed at basal level at all times but reached optimal expression levels after 3.5 hours of induction  
186 (data not shown). To improve the diagnostic potential of the rBpRAG1 antigen a few changes were made  
187 in the composition of the purification and wash buffers by adding 10 mM β-mercaptoethanol and 20  
188 mM imidazole. The goal was to eliminate all the bands detected in the immunoblot when probed with  
189 healthy human sera but to keep a strong signal with the 37 kDa rBpRAG1 antigen when *B. procyonis*  
190 positive samples are tested. The purified and desalted rBpRAG1 antigen (37 kDa) showed a strong  
191 reaction to the human *B. procyonis* positive antisera pool (Figure 1). When probed with individual or



192 pooled healthy human sera no band was detected at 37 kDa confirming the specificity of the rBpRAG1  
193 antigen for *B. procyonis*. However, a single unidentified band slightly larger than 75 kDa was observed  
194 (Figure 1). The presence of this 75 kDa band suggested that an optimal test would still require  
195 separation of proteins, thus eliminating ELISA as a potential assay format. To further simplify the assay,  
196 the detection method was switched from ECL to DAB keeping in mind the facility and rapidity of use of  
197 the latter method. The next step was to find the optimal rBpRAG1 antigen amount to use for detecting  
198 the 37 kDa rBpRAG1 antigen in *B. procyonis* positive individuals (but not in negative patients), and to  
199 eliminate reactivity with the 75 kDa band in negative patients sera. We found that any amount between  
200 128 and 256 ng/well of rBpRAG1 antigen was sufficient to achieve that outcome (Figure 2A).

201 Experiments were also conducted at CDC to determine antigen purity and optimal  
202 concentration; four concentrations of the rBpRAG1 protein were evaluated, 18.3, 37.5, 75, 150 ng/well,  
203 using Western blot (Figure 2B). *Baylisascaris*-specific antibodies reacted with the rBpRAG1 protein with  
204 an approximate molecular mass of 37 kDa. No cross-reactivity was seen with the normal human serum  
205 pool or *Toxocara* strong-positive serum pool. Based on protein resolution and band intensity, the 75  
206 ng/well concentration of rBpRAG1 was chosen for further evaluation. Experiments were also performed  
207 to determine if a pre-blocking step was necessary. Pre-blocking the membrane for 1 hour with PBS-  
208 Tw/5% milk prior to the addition of serum or CSF improved assay performance and was therefore  
209 incorporated into the final protocol.

210 Assay performance was evaluated independently at both CDC and NRCP (Tables 1 and 2).  
211 Sensitivity was assessed using specimens from 16 patients with baylisascariasis. A total of 15 sera and  
212 one CSF were tested at CDC and nine sera and two CSF from patients at NRCP. Of the 16 *B. procyonis*  
213 positive patients tested, 14 were positive using the rBpRAG1 Western blot, resulting in a sensitivity of  
214 88%. Serum specimens from seven patients with baylisascariasis were tested at both laboratories and all  
215 tests were positive. It was not possible to test all specimens at both institutions due to insufficient

216 quantities of some sera and CSF. A panel of 373 sera was tested from patients with varying diseases,  
217 including 63 *Toxocara* positive samples. No sera from patients with toxocariasis were positive  
218 (Figure3A); three sera from patients with malaria, and single sera from patients with giardiasis, filariasis,  
219 and strongyloidiasis reacted with rBpRAG1 (Figures 3B). Eight sera from presumed normal individuals  
220 were also reactive. Overall 14 sera reacted with rBpRAG1, resulting in a specificity of 98%.

## 221 Discussion

222 The performance of the rBpRAG1 Western blot greatly improves laboratory diagnosis for  
223 baylisascariasis. Assays based on native ES antigen showed cross-reactivity with antibodies from patients  
224 with toxocariasis which necessitated additional testing with *Toxocara* antigens to determine if  
225 antibodies specific to *Toxocara* were present; if so, a diagnosis of baylisascariasis could not be  
226 definitively made. The lack of cross-reactivity in the rBpRAG1 assay eliminates the necessity for  
227 additional testing to rule out toxocariasis and increases the confidence of a baylisascariasis diagnosis.  
228 The inter-laboratory evaluation of the assays showed that the results from both centers were  
229 concordant and demonstrated the robustness of the assay. Our results indicated a sensitivity and  
230 specificity of the assay of 88% and 98%, respectively. However, they may actually be higher than this,  
231 since we do not know the full infection history of test sera, e.g., if positive cross-reactors with other  
232 parasites or conditions were also infected with *Baylisascaris* as covert dual infections. Sera from two  
233 patients gave false negative results in our assay. This may be related to infection levels or the kinetics of  
234 the immune response to the parasite. Future studies to examine the kinetics of the immune response  
235 and appearance of detectable antibody could provide insight into the false-negative results seen with  
236 our assay.

237 The availability of a more sensitive and specific assay will also facilitate serosurveys to better  
238 examine the epidemiology of baylisascariasis. Covert infections with *B. procyonis*, showing mild or no  
239 symptoms, may be expected based on the widespread distribution of raccoons in North America, the

240 prevalence of *B. procyonis* in raccoons (68-90%), and the level of human exposure to *B. procyonis* eggs  
241 (2,4,5). Covert infections have been shown in previous reports, e.g., one study showed 8%  
242 seroprevalence in children in the Chicago area (1), and the parents of a child with severe NLM symptoms  
243 tested positive for *B. procyonis* antibodies without showing signs or symptoms of infection (10).  
244 Although an assay in an ELISA platform would be more efficient for a service diagnostic laboratory and  
245 for serosurveys, there are several bands seen by Western blotting that seem to be reactive when testing  
246 any human serum sample, including normal human serum and *Toxocara*-positive serum (Figure 2). The  
247 presence of these bands suggests there would be a lower performance if used in the ELISA format and  
248 could explain the slightly lower specificity seen with the BpRAG1 ELISA which shows cross-reactivity to  
249 toxocariasis at 25% (5); therefore, further modification must be performed on the rBpRAG1 antigen  
250 before an ELISA assay can be developed.

251           Currently, the rBpRAG1 diagnostic Western blot is being used for testing at the CDC and NRCP.  
252 *B. procyonis* infection should be considered based on the presence of NLM, VLM, or OLM symptoms  
253 with supporting epidemiological evidence such as a history of pica/geophagia and exposure to raccoons  
254 or raccoon latrines. With a high specificity and no cross-reaction in *Toxocara* infections, a positive  
255 rBpRAG1 test result should be considered indicative of infection with *B. procyonis* in patients with  
256 consistent clinical presentation and risk factors.

257

#### 258 **Acknowledgments**

259           We wish thank Dr. Mark Eberhard of CDC for providing the *B. procyonis* experimentally infected  
260 baboon serum. Work performed at the NRCP is supported by the Public Health Agency of  
261 Canada/National Microbiology Laboratory, grant HT070-010033.

262 **References**

- 263 1. **Brinkman WB, Kazacos KR, Gavin PJ, Binns HJ, Robichaud JD, O'Gorman M, Shulman ST.** 2003.  
264 Seroprevalence of *Baylisascaris procyonis* (raccoon roundworm) in Chicago area children, abstr  
265 1872, Ann. Meet. Pediatr. Acad. Soc.
- 266 2. **Cunningham CK, Kazacos KR, McMillan JA, Lucas JA, McAuley JB, Wozniak EJ, Weiner LB.** 1994.  
267 Diagnosis and management of *Baylisascaris procyonis* infection in an infant with nonfatal  
268 meningoencephalitis. Clin. Infect. Dis. **18**:868-872.
- 269 3. **Dangoudoubiyam S, Kazacos KR.** 2009. Differentiation of larva migrans caused by *Baylisascaris*  
270 *procyonis* and *Toxocara* species by Western blotting. Clin Vaccine Immunol. **16**:1563-1568.
- 271 4. **Dangoudoubiyam S, Vemulapalli R, Hancock K, Kazacos KR.** 2010. Molecular cloning of an  
272 immunogenic protein of *Baylisascaris procyonis* and expression in *Escherichia coli* for use in  
273 developing improved serodiagnostic assays. Clin. Vaccine Immunol. **17**:1933-1939.
- 274 5. **Dangoudoubiyam S, Vemulapalli R, Ndao M, Kazacos KR.** 2011. Recombinant antigen-based  
275 enzyme-linked immunosorbent assay for diagnosis of *Baylisascaris procyonis* larva migrans. Clin.  
276 Vaccine Immunol. **18**:1650-1655.
- 277 6. **Watts CS, Liang JL, Schantz PM.** 2006. Baylisascariasis: an emerging and potentially fatal form of  
278 larval migrans. In Holland CV, Smith HV (ed), *Toxocara: the enigmatic parasite*. CAB  
279 International, Wallingford, UK.
- 280 7. **Gavin PJ, Kazacos KR, Shulman ST.** 2005. Baylisascariasis. Clin. Microbiol. Rev. **18**:703-718.
- 281 8. **Tsang VC, Peralta JM, Simons AR.** 1983. Enzyme-linked immunoelectrotransfer blot techniques  
282 (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis.  
283 Methods Enzymol. **92**:377-391.
- 284 9. **Kazacos KR.** 2001. *Baylisascaris procyonis* and related species, p 301-341. In Samuel WM, Pybus  
285 MJ, Kocan AA (ed), Parasitic diseases of wild mammals, 2<sup>nd</sup> ed. Iowa State Univ. Press, Ames, IA.

286 10. **Murray WJ, Kazacos KR.** 2004. Raccoon roundworm encephalitis. Clin. Infect. Dis. **39**:1484-1492.

287

288 **Figure Legends**

289 **Figure 1.** Purified and desalted rBpRAG1 antigen produced at NRCP was tested for reactivity against  
290 human serum pools: (+) *B. procyonis* positive sera or (-) healthy control sera. The membranes were  
291 detected by ECL. A 37 kDa band corresponding to rBpRAG1 was only detected when probed with sera  
292 from individuals with baylisascariasis. A single unidentified band running slightly above 75 kDa was  
293 detected by both the positive and negative serum pools.

294 **Figure 2.** Determination of the optimal rBpRAG1 concentration. **(A)** At NRCP, a titration of the purified  
295 rBpRAG1 antigen was performed with 128, 256, 512 and 1024 ng/well and the blots were probed with  
296 (+) *B. procyonis* positive human serum pool and (-) healthy human serum pool. **(B)** At CDC, a titration of  
297 the purified rBpRAG1 antigen was performed at concentrations of (1) 150 ng/well, (2) 75 ng/well, (3)  
298 37.5 ng/well, and (4) 18.3 ng/well. Western blots were probed with (A) normal human serum pool, (B)  
299 anti-*B. procyonis* baboon serum, and (C) *Toxocara* strong-positive serum pool.

300 **Figure 3.** **(A)** At CDC, reactivity of serum specimens from patients with *B. procyonis* (A) and *Toxocara* (B)  
301 were tested using rBpRAG1 Western blot strips. Strip A1 is a sample from a patient diagnosed with  
302 baylisascariasis; strip A3 is a sample from the same patient 3 years post-infection. Patients positive for  
303 *Toxocara* by EIA (CDC) were tested using the rBpRAG1 strips (B1-B10). The positive and negative  
304 controls were an anti-*B. procyonis* baboon serum (Strip B11) and a normal human serum sample (B12),  
305 respectively. **(B)** At NRCP, reactivity of serum specimens to rBpRAG1 from patients with Chagas (1-3),  
306 trichuriasis (4-5), strongyloidiasis (6-8), toxocariasis (9-11), echinococcosis (12-14) and filariasis (15-16).  
307 Western blot controls included healthy human serum pool (-) and *B. procyonis* baboon serum (+).  
308 Positive reactions are observed in lane 15.

309

310 Table 1. Reactivity of sera from patients with baylisascariasis in the rBpRAG1 assays tested at CDC and  
 311 NRCP.

Patient #	Collection Date	CDC Result	NRCP Result
1	10/17/1990	Positive	Positive
2	10/23/1993	Positive	Positive
3	1/24/1997	Positive	Positive
4	8/7/1997	Negative	N.T.
5	10/20/1997	Positive	N.T.
6	9/1/1998	Positive	Positive
7	1/27/2000	Positive	Positive
	1/31/2000	N.T.	Positive
8	7/17/2000	Positive	Positive
	07/24/2000 (CSF)	N.T.	Positive
	7/26/2000	N.T.	Positive
9	5/28/2002	Positive	Positive
	07/17/2002 (CSF)	N.T.	Positive
10	4/12/2004	Negative	N.T.
11	9/24/2004	Positive	N.T.
12	8/13/2005	Positive	N.T.
13	8/15/2007	Positive	N.T.
14	1/17/2008	Positive	N.T.
15	9/16/2008	Positive	N.T.
16	10/23/2008 (CSF)	Positive	N.T.

312 N.T., not tested. CSF, cerebral spinal fluid. All specimens are serum/plasma unless indicated.

313 Table 2. Analysis of the specificity of the rBpRAG1 assays determined at CDC and NRCP.

Disease	CDC		NRCP	
	# Samples	Positives	# Samples	Positives
Normal	150	6	130	2
Amebiasis	NT	NT	15	0
Ancylostomiasis	1	0	NT	NT
Ascariasis	18	0	11	0
Cancer	2	0	NT	NT
Chagas Disease	NT	NT	25	0
Cysticercosis	2	0	8	0
Echinococcosis	3	0	24	0
Eosinophilic Myalgia	2	0	NT	NT
Fascioliasis	1	0	35	0
Filariasis	NT	NT	7	1
Giardiasis	NT	NT	17	1
Gnathostomiasis	4	0	NT	NT
Hookworm	11	0	NT	NT
Hymenolepiasis	1	0	NT	NT
Malaria	NT	NT	10	3
Schistosomiasis	4	0	21	0
Strongyloidiasis	8	1	25	0
Toxocariasis	40	0	23	0
Toxoplasmosis	4	0	12	0
Trichinellosis	4	0	22	0
Trichuriasis	4	0	9	0
Totals (n)	259	7	394	7
<b>Specificity (%)</b>	<b>97</b>		<b>98</b>	

314











